Frontline Tebentafusp Significantly Improves OS in Metastatic Uveal Melanoma
Source: OncLive, April 2021
Tebentafusp (IMCgp100) resulted in a highly significant and clinically meaningful improvement in overall survival (OS) when given as a frontline treatment in patients with metastatic uveal melanoma, according to data from the phase 3 IMCgp100-202 trial (NCT03070392) presented during a press briefing ahead of the virtual AACR Annual Meeting 2021.1
